Mary T. Szela, Senior Vice President at ABBOTT LABORATORIES (ABT), sold 29,100 shares at $48.12 ($1.4M) on 2011-03-01, disclosed to the SEC on 2011-03-02.
Scheduled sale ($1.4M) by Senior Vice President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.64 | 9,845 | $469K | 33.6% |
| 2 | $48.30 | 1,988 | $96K | 6.9% |
| 3 | $48.11 | 11,067 | $532K | 38.1% |
| 4 | $48.11 | 100 | $5K | 0.3% |
| 5 | $48.12 | 2,800 | $135K | 9.7% |
| 6 | $48.13 | 100 |
| $5K |
| 0.3% |
| 7 | $48.14 | 2,500 | $120K | 8.6% |
| 8 | $48.17 | 700 | $34K | 2.4% |
| Total | $47.97 avg | 29,100 | $1.4M | 100% |
| Filing → |
| TLSI | SELL | 2026-03-20 | $79K | — | Filing → |
| TLSI | BUY | 2026-02-23 | $125K | — | Filing → |
| TLSI | BUY | 2025-01-31 | $52K | — | Filing → |